{"totalCount":3,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT06395948","orgStudyIdInfo":{"id":"APG777-201"},"organization":{"fullName":"Apogee Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study Evaluating APG777 in Atopic Dermatitis","officialTitle":"A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients With Moderate-to-severe Atopic Dermatitis"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-04-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-04-29","studyFirstSubmitQcDate":"2024-04-29","studyFirstPostDateStruct":{"date":"2024-05-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-15","lastUpdatePostDateStruct":{"date":"2025-12-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Apogee Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD). Part A (Proof-of-concept) and Part B (Dose-regimen Finding) will evaluate the safety and efficacy of various induction and maintenance dose regimens of APG777 compared to placebo. The study duration for any individual participant will be up to 106 weeks which includes: screening, induction, maintenance, and post-treatment follow-up periods. Participants randomized in Part A are not permitted to participate in Part B."},"conditionsModule":{"conditions":["Atopic Dermatitis"],"keywords":["Atopic Dermatitis","APG777","Safety","Efficacy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"The Sponsor's study staff will also be blinded in the study.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":470,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A: Induction Period: APG777","type":"EXPERIMENTAL","description":"Participants will receive APG777 per protocol defined dosing regimen","interventionNames":["Drug: APG777"]},{"label":"Part A: Induction Period: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching Placebo injections per protocol defined dosing regimen","interventionNames":["Drug: Placebo"]},{"label":"Part A: Maintenance Period: APG777","type":"EXPERIMENTAL","description":"Participants will receive 1 of 2 maintenance regimens of APG777 per protocol defined dosing regimen","interventionNames":["Drug: APG777"]},{"label":"Part B: Induction Period: APG777","type":"EXPERIMENTAL","description":"Participants will receive APG777 in 1 of 3 regimens per protocol defined dosing regimen","interventionNames":["Drug: APG777"]},{"label":"Part B: Induction Period: Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo injections per protocol defined dosing regimen","interventionNames":["Drug: Placebo"]},{"label":"Part B: Maintenance Period: APG777","type":"EXPERIMENTAL","description":"Participants will receive APG777 per protocol defined dosing regimen","interventionNames":["Drug: APG777"]}],"interventions":[{"type":"DRUG","name":"APG777","description":"APG777 subcutaneous injection","armGroupLabels":["Part A: Induction Period: APG777","Part A: Maintenance Period: APG777","Part B: Induction Period: APG777","Part B: Maintenance Period: APG777"]},{"type":"DRUG","name":"Placebo","description":"Matching placebo subcutaneous injection","armGroupLabels":["Part A: Induction Period: Placebo","Part B: Induction Period: Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part A: Percent Change From Baseline in Eczema Area and Severity Index (EASI)","timeFrame":"Baseline and at Week 16"},{"measure":"Part B: Proportion of participants who achieve EASI 75 at Week 16","timeFrame":"At Week 16"}],"secondaryOutcomes":[{"measure":"Part A and B: Number of Participants with Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 106 Weeks"},{"measure":"Part A and B: Change from Baseline in EASI","timeFrame":"Baseline, through Week 16 and at Week 52"},{"measure":"Part A and B: Percent Change from Baseline in EASI","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Proportion of Participants Achieving EASI 50, 75, 90, and 100 Score","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Proportion of Participants Achieving a Validated Investigator Global Assessment (vIGA-AD) Score of 0 (clear) or 1 (almost clear) and a >= 2-Point Reduction","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Change from Baseline in Body Surface Area (BSA) Involvement","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Proportion of Participants Achieving a >= 4 Point Improvement in the Weekly Mean of the Daily Itch Numeric Rating Scale (I-NRS)","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Percent Change from Baseline in the Weekly Mean of the Daily I-NRS","timeFrame":"Baseline through Week 16 and at Week 52"},{"measure":"Part A and B: Serum Concentrations of APG777 Over Time","timeFrame":"Up to 106 Weeks"},{"measure":"Part A and B: Predose Serum Concentrations of APG777 (Ctrough)","timeFrame":"Up to 106 Weeks"},{"measure":"Part A and B: Maximum concentration (Cmax) of APG777","timeFrame":"Up to 106 Weeks"},{"measure":"Part A and B: Time to reach Cmax (tmax)","timeFrame":"Up to 106 Weeks"},{"measure":"Part A and B: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUC0-t) in the Induction Period","timeFrame":"Baseline to 16 Weeks"},{"measure":"Part A and B: AUC Over the Dosing Interval (AUC0-tau) in the Maintenance Period","timeFrame":"16 Weeks to 52 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of AD that has been present for \\>=1 year prior to the Screening visit\n* Moderate-to-severe AD at Screening and Baseline visits\n* History of inadequate response to treatment with topical medications, or medical determination that topical therapies are inadvisable\n* Applied a stable dose of non-medicated over-the-counter emollient/moisturizer of their choice on their skin for \\>=14 days prior to Baseline visit and agrees to continue using the same moisturizer throughout the study except the day of the study visits.\n* Have completed itch questionnaires in the electronic diary for \\>=4 of 7 days prior to Baseline visit\n\nExclusion Criteria:\n\n* Participation in a prior study with APG777.\n* Prior treatment with protocol-specified monoclonal antibodies (mAbs)\n* Has used any AD-related topical medications within 7 days prior to Baseline visit.\n* Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit\n\nNote: Other protocol defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigational Site","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Investigational Site","city":"Los Angeles","state":"California","zip":"90024","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Investigational Site","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Investigational Site","city":"New Haven","state":"Connecticut","zip":"06519","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Investigational Site","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Investigational Site","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Investigational Site","city":"Margate","state":"Florida","zip":"33063","country":"United States","geoPoint":{"lat":26.24453,"lon":-80.20644}},{"facility":"Investigational Site","city":"Douglasville","state":"Georgia","zip":"30135","country":"United States","geoPoint":{"lat":33.7515,"lon":-84.74771}},{"facility":"Investigational Site","city":"Chicago","state":"Illinois","zip":"60657","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Investigational Site","city":"Skokie","state":"Illinois","zip":"60077","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"Investigational Site","city":"West Lafayette","state":"Indiana","zip":"47906","country":"United States","geoPoint":{"lat":40.42587,"lon":-86.90807}},{"facility":"Investigational Site","city":"Bowling Green","state":"Kentucky","zip":"42104","country":"United States","geoPoint":{"lat":36.99032,"lon":-86.4436}},{"facility":"Investigational Site","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Investigational Site","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Investigational Site","city":"Troy","state":"Michigan","zip":"48084","country":"United States","geoPoint":{"lat":42.60559,"lon":-83.14993}},{"facility":"Investigational Site","city":"Portsmouth","state":"New Hampshire","zip":"13801","country":"United States","geoPoint":{"lat":43.07704,"lon":-70.75766}},{"facility":"Investigational Site","city":"New York","state":"New York","zip":"10023","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Investigational Site","city":"Wilmington","state":"North Carolina","zip":"28403","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Investigational Site","city":"Boardman","state":"Ohio","zip":"44512","country":"United States","geoPoint":{"lat":41.02423,"lon":-80.66285}},{"facility":"Investigational Site","city":"Mason","state":"Ohio","zip":"45040","country":"United States","geoPoint":{"lat":39.36006,"lon":-84.30994}},{"facility":"Investigational Site","city":"Portland","state":"Oregon","zip":"97201","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15213","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Investigational Site","city":"Charleston","state":"South Carolina","zip":"29425","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"Investigational Site","city":"Nashville","state":"Tennessee","zip":"37215","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Investigational Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Investigational Site","city":"Dallas","state":"Texas","zip":"75235","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Investigational Site","city":"San Antonio","state":"Texas","zip":"78213","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Investigational Site","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Investigational Site","city":"Mill Creek","state":"Washington","zip":"98012","country":"United States","geoPoint":{"lat":47.8601,"lon":-122.2043}},{"facility":"Investigational Site","city":"Calgary","state":"Alberta","zip":"T2J 7E1","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Investigational Site","city":"Calgary","state":"Alberta","zip":"T3E 0B2","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Investigational Site","city":"Edmonton","state":"Alberta","zip":"T5J 3S9","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Investigational Site","city":"Vancouver","state":"British Columbia","zip":"V5Z 4E8","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Investigational Site","city":"Winnipeg","state":"Manitoba","zip":"R3M 3Z4","country":"Canada","geoPoint":{"lat":49.8844,"lon":-97.14704}},{"facility":"Investigational Site","city":"Fredericton","state":"New Brunswick","zip":"E3B 1G9","country":"Canada","geoPoint":{"lat":45.94541,"lon":-66.66558}},{"facility":"Investigational Site","city":"Ajax","state":"Ontario","zip":"L1S 7K8","country":"Canada","geoPoint":{"lat":43.85012,"lon":-79.03288}},{"facility":"Investigational Site","city":"Markham","state":"Ontario","zip":"L3P 1X3","country":"Canada","geoPoint":{"lat":43.86682,"lon":-79.2663}},{"facility":"Investigational Site","city":"Mississauga","state":"Ontario","zip":"L4Y 4C5","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"Investigational Site","city":"Ottawa","state":"Ontario","zip":"K1K 4L2","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Investigational Site","city":"Peterborough","state":"Ontario","zip":"K9J 5K2","country":"Canada","geoPoint":{"lat":44.30012,"lon":-78.31623}},{"facility":"Investigational Site","city":"Toronto","state":"Ontario","zip":"M3B 0A7","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","city":"Toronto","state":"Ontario","zip":"M4E 2Y9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","city":"Toronto","state":"Ontario","zip":"M4W 2N4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","city":"Montreal","state":"Quebec","zip":"H2X 2V1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Investigational Site","city":"Québec","state":"Quebec","zip":"G1V4X7","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Investigational Site","city":"Prague","zip":"10000","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Investigational Site","city":"Prague","zip":"10034","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Investigational Site","city":"Prague","zip":"11000","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Investigational Site","city":"Prague","zip":"15006","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Investigational Site","city":"Prague","zip":"16000","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Investigational Site","city":"Rouen","state":"Normandy","zip":"76031","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Investigational Site","city":"Martigues","zip":"13500","country":"France","geoPoint":{"lat":43.40735,"lon":5.05526}},{"facility":"Investigational Site","city":"Nantes","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Investigational Site","city":"Freiburg im Breisgau","state":"Baden-Wurttemberg","zip":"79104","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"facility":"Investigational Site","city":"Heidelberg","state":"Baden-Wurttemberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Investigational Site","city":"Tübingen","state":"Baden-Wurttemberg","zip":"72076","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Investigational Site","city":"Augsburg","state":"Bavaria","zip":"86179","country":"Germany","geoPoint":{"lat":48.37154,"lon":10.89851}},{"facility":"Investigational Site","city":"München","state":"Bavaria","zip":"81377","country":"Germany","geoPoint":{"lat":48.69668,"lon":13.46314}},{"facility":"Investigational Site","city":"Blankenfelde-Mahlow","state":"Brandenburg","zip":"15831","country":"Germany","geoPoint":{"lat":52.33645,"lon":13.41316}},{"facility":"Investigational Site","city":"Darmstadt","state":"Hesse","zip":"64283","country":"Germany","geoPoint":{"lat":49.87167,"lon":8.65027}},{"facility":"Investigational Site","city":"Frankfurt am Main","state":"Hesse","zip":"60590","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Investigational Site","city":"Bad Bentheim","state":"Lower Saxony","zip":"48455","country":"Germany","geoPoint":{"lat":52.30066,"lon":7.15763}},{"facility":"Investigational Site","city":"Münster","state":"North Rhine Westfalia","zip":"48149","country":"Germany","geoPoint":{"lat":51.96236,"lon":7.62571}},{"facility":"Investigational Site","city":"Dresden","state":"Saxony","zip":"01307","country":"Germany","geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"Investigational Site","city":"Kiel","state":"Schleswig-Holstein","zip":"24105","country":"Germany","geoPoint":{"lat":54.32133,"lon":10.13489}},{"facility":"Investigational Site","city":"Lübeck","state":"Schleswig-Holstein","zip":"23538","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"Investigational Site","city":"Berlin","zip":"10117","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Investigational Site","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Investigational Site","city":"Hamburg","zip":"20354","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Investigational Site","city":"Debrecen","state":"Hajdú-Bihar","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Investigational Site","city":"Budapest","zip":"1085","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"Investigational Site","city":"Szeged","zip":"6720","country":"Hungary","geoPoint":{"lat":46.253,"lon":20.14824}},{"facility":"Investigational Site","city":"Wroclaw","state":"Lower Silesian Voivodeship","zip":"50-450","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Investigational Site","city":"Wroclaw","state":"Lower Silesian Voivodeship","zip":"51-503","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Investigational Site","city":"Lublin","state":"Lublin Voivodeship","zip":"20-573","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Investigational Site","city":"Warsaw","state":"Masovian Voivodeship","zip":"01-595","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Investigational Site","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-482","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Investigational Site","city":"Gdansk","state":"Pomeranian Voivodeship","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Investigational Site","city":"Katowice","state":"Silesian Voivodeship","zip":"40-600","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Investigational Site","city":"Sosnowiec","state":"Silesian Voivodeship","zip":"41-218","country":"Poland","geoPoint":{"lat":50.28682,"lon":19.10385}},{"facility":"Investigational Site","city":"Szczecin","state":"West Pomeranian Voivodeship","zip":"71-500","country":"Poland","geoPoint":{"lat":53.42894,"lon":14.55302}},{"facility":"Investigational Site","city":"Krakow","state":"Woj. Małopolskie","zip":"30-727","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Investigational Site","city":"Lodz","state":"Łódź Voivodeship","zip":"90-338","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Investigational Site","city":"Santiago de Compostela","state":"A Coruña","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Investigational Site","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Investigational Site","city":"Las Palmas de Gran Canaria","state":"Canary Islands","zip":"35010","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Investigational Site","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Investigational Site","city":"Barcelona","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Investigational Site","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Investigational Site","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Investigational Site","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Investigational Site","city":"Salford","state":"Greater Manchester","zip":"M6 8HD","country":"United Kingdom","geoPoint":{"lat":53.48771,"lon":-2.29042}},{"facility":"Investigational Site","city":"Dudley","state":"West Midlands","zip":"DY1 2HQ","country":"United Kingdom","geoPoint":{"lat":52.5,"lon":-2.08333}},{"facility":"Investigational Site","city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003876","term":"Dermatitis, Atopic"}],"ancestors":[{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D003872","term":"Dermatitis"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D017443","term":"Skin Diseases, Eczematous"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT07027527","orgStudyIdInfo":{"id":"APG279-101"},"organization":{"fullName":"Apogee Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis","officialTitle":"A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-06-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-06-11","studyFirstSubmitQcDate":"2025-06-11","studyFirstPostDateStruct":{"date":"2025-06-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-18","lastUpdatePostDateStruct":{"date":"2026-01-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Apogee Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).","detailedDescription":"Participants will be randomized to APG777 + APG990 or dupilumab in a 1:1 ratio. Randomization will be stratified on Day 1 according to Baseline disease severity and geographic region."},"conditionsModule":{"conditions":["Atopic Dermatitis"],"keywords":["Atopic Dermatitis","Moderate-to-Severe AD","APG777","Dupilumab","APG990"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":80,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"APG777 + APG990","type":"EXPERIMENTAL","description":"Participants will receive protocol specified combination dose of APG777 + APG990","interventionNames":["Drug: APG777","Drug: APG990"]},{"label":"Dupilumab","type":"ACTIVE_COMPARATOR","description":"Participants will receive protocol specified dose of Dupilumab","interventionNames":["Drug: Dupilumab"]}],"interventions":[{"type":"DRUG","name":"APG777","description":"Subcutaneous (SC) injection","armGroupLabels":["APG777 + APG990"]},{"type":"DRUG","name":"APG990","description":"SC injection","armGroupLabels":["APG777 + APG990"]},{"type":"DRUG","name":"Dupilumab","description":"SC injection","armGroupLabels":["Dupilumab"],"otherNames":["Dupixent"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 24 weeks"}],"secondaryOutcomes":[{"measure":"Predose Serum Concentrations (Ctrough) of APG777","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software.","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"},{"measure":"Predose Serum Concentrations (Ctrough) of APG990","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software.","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"},{"measure":"Maximum Serum Concentrations (Cmax) of APG777","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"},{"measure":"Maximum Serum Concentrations (Cmax) of APG990","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software.","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"},{"measure":"Time to Reach Cmax (tmax) of APG777","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"},{"measure":"Time to Reach Cmax (tmax) of APG990","description":"PK parameters will be performed using a non-compartmental approach with a validated PK software. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.","timeFrame":"Baseline, Week 1, 2, 4, 8, 12, 16, 20, 24"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Have a diagnosis of AD that has been present for ≥ 1 year prior to the Screening visit and as determined by the Investigator through participant interview and/or review of the medical history.\n* Moderate-to-severe AD at Screening and Baseline (Day 1) visits, defined as: a) Eczema Area and Severity Index (EASI) score of ≥ 16, b) vIGA-AD score of ≥ 3, and c) AD affecting ≥10% of body surface area (BSA).\n* History of inadequate response to treatment with topical medications\n* Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline (Day 1) visit.\n\nExclusion Criteria\n\n* Participation in a prior study with APG777 or APG990.\n* Prior treatment with protocol-specified monoclonal antibodies (mAbs).\n* Has used any AD-related topical medications within 7 days prior to Baseline visit.\n* Has used systemic treatments (other than biologics) and/or phototherapies and/or laser therapy that could affect AD within 4 weeks prior to Baseline visit\n* History of known hypersensitivity to any of the ingredients in APG777, APG990, or dupilumab.\n* Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or might interfere with study assessments\n\nNote: Additional protocol defined Inclusion/Exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Director","role":"CONTACT","phone":"+1 781 208 2408","email":"ClinicalTrials@apogeetherapeutics.com"}],"locations":[{"facility":"Investigational Site","status":"RECRUITING","city":"Darlinghurst","state":"New South Wales","zip":"2010","country":"Australia","geoPoint":{"lat":-33.87939,"lon":151.21925}},{"facility":"Investigational Site","status":"RECRUITING","city":"Kogarah","state":"New South Wales","zip":"2217","country":"Australia","geoPoint":{"lat":-33.9681,"lon":151.13564}},{"facility":"Investigational Site","status":"RECRUITING","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Investigational Site","status":"RECRUITING","city":"Woolloongabba","state":"Queensland","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"Investigational Site","status":"RECRUITING","city":"Carlton","state":"Victoria","zip":"3053","country":"Australia","geoPoint":{"lat":-37.8,"lon":144.96667}},{"facility":"Investigational Site","status":"RECRUITING","city":"East Melbourne","state":"Victoria","zip":"3002","country":"Australia","geoPoint":{"lat":-37.81667,"lon":144.9879}},{"facility":"Investigational Site","status":"RECRUITING","city":"Mitcham","state":"Victoria","zip":"3132","country":"Australia","geoPoint":{"lat":-37.81667,"lon":145.2}},{"facility":"Investigational Site","status":"RECRUITING","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Investigational Site","status":"RECRUITING","city":"Fremantle","state":"Western Australia","zip":"6160","country":"Australia","geoPoint":{"lat":-32.05632,"lon":115.74557}},{"facility":"Investigational Site","status":"RECRUITING","city":"London","state":"Ontario","zip":"N6H 5L5","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Investigational Site","status":"RECRUITING","city":"Peterborough","state":"Ontario","zip":"K9J 5K2","country":"Canada","geoPoint":{"lat":44.30012,"lon":-78.31623}},{"facility":"Investigational Site","status":"RECRUITING","city":"Richmond Hill","state":"Ontario","zip":"L4B 1A5","country":"Canada","geoPoint":{"lat":43.87111,"lon":-79.43725}},{"facility":"Investigational Site","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M4E 1R7","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M4W 2N4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M5A 3R6","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigational Site","status":"RECRUITING","city":"Montreal","state":"Quebec","zip":"H1Y 3L1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Investigational Site","status":"RECRUITING","city":"Québec","state":"Quebec","zip":"G1W 1S2","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Investigational Site","status":"RECRUITING","city":"Sherbrooke","state":"Quebec","zip":"J1G 1X9","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"Investigational Site","status":"RECRUITING","city":"Hamilton","state":"Waitako","zip":"3204","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Investigational Site","status":"RECRUITING","city":"Auckland","zip":"1051","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D003876","term":"Dermatitis, Atopic"}],"ancestors":[{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D003872","term":"Dermatitis"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D017443","term":"Skin Diseases, Eczematous"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582203","term":"dupilumab"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06920901","orgStudyIdInfo":{"id":"APG777-105"},"organization":{"fullName":"Apogee Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma","officialTitle":"A Phase 1b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of APG777 in Adults With Mild-to-Moderate Asthma"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-03-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-03-27","studyFirstSubmitQcDate":"2025-04-08","studyFirstPostDateStruct":{"date":"2025-04-10","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-12","lastUpdatePostDateStruct":{"date":"2026-02-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Apogee Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.\n\nThe duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period."},"conditionsModule":{"conditions":["Asthma"],"keywords":["Asthma","Mild to moderate asthma","Tolerability","Immunogenicity","Pharmacokinetics"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":31,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"APG777","type":"EXPERIMENTAL","description":"Participants will receive protocol specified dose of APG7777","interventionNames":["Drug: APG777"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive matching placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"APG777","description":"APG777 subcutaneous injection","armGroupLabels":["APG777"]},{"type":"DRUG","name":"Placebo","description":"Matching placebo subcutaneous injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants with Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 52 weeks"},{"measure":"Number of Participants with Abnormal Laboratory Findings","timeFrame":"Up to 52 weeks"},{"measure":"Number of Participants with Abnormal Vital Signs","timeFrame":"Up to 52 weeks"},{"measure":"Number of Participants with Abnormal Electrocardiograms (ECGs)","timeFrame":"Up to 52 weeks"},{"measure":"Number of Participants with Abnormal Physical Examination Findings","timeFrame":"Up to 52 weeks"}],"secondaryOutcomes":[{"measure":"Maximum concentration (Cmax) of APG777","timeFrame":"Up to 48 weeks"},{"measure":"Time to reach Cmax (tmax)","timeFrame":"Up to 48 weeks"},{"measure":"Terminal elimination rate constant (λz)","timeFrame":"Up to 48 weeks"},{"measure":"Terminal Elimination half-life (t1/2)","timeFrame":"Up to 48 weeks"},{"measure":"Area Under the Serum Concentration-time curve (AUC) from Time 0 to the Last Quantifiable Time Point (AUC0-last)","timeFrame":"Up to 48 weeks"},{"measure":"AUC From Time 0 Extrapolated to Infinity (AUC0-inf)","timeFrame":"Up to 48 weeks"},{"measure":"Apparent Clearance of APG777 (CL/F)","timeFrame":"Up to 48 weeks"},{"measure":"Apparent Volume of Distribution (Vz/F)","timeFrame":"Up to 48 weeks"},{"measure":"Number of Participants with Anti-Drug-Antibodies (ADAs)","timeFrame":"Up to 48 weeks"},{"measure":"Cmax in Participants With and without ADAs","timeFrame":"Up to 48 weeks"},{"measure":"AUClast Participants With and without ADAs","timeFrame":"Up to 48 weeks"},{"measure":"AUCInf Participants With and without ADAs","timeFrame":"Up to 48 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a diagnosis of mild-to-moderate asthma (Global Initiative for Asthma 2023 criteria) ≥ 1 year prior to Screening\n* Maintain FeNO-high (≥ 25 parts per billion \\[ppb\\]) or FeNO-low (\\< 25 ppb) status from Screening to Day 1 prior to Randomization\n* Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 60% of predicted normal value at Screening\n* Asthma Control Test (ACT) score \\> 19 at Screening\n* Maintained control on as-needed short-acting beta-agonist (SABA) +/- stable dose inhaled corticosteroids (ICS) or stable dose of ICS/ long-acting beta-agonist (LABA); +/- stable dose leukotriene receptor antagonist (LTRA). ICS dose should be stable for ≥ 12 weeks prior to Day 1, LTRA dose should be stable for ≥ 8 weeks prior to Day 1\n* Women of childbearing potential and male participants to use a highly effective form of contraception\n\nExclusion Criteria:\n\n* Any asthma exacerbation requiring systemic corticosteroids within 12 weeks of Screening and/or any asthma exacerbation that resulted in overnight hospitalization within 6 months prior to Screening\n* Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia\n* History of biologics use for treatment or control of asthma\n* Current smokers or participants with a smoking history of ≥ 10 pack years\n* Known history of illicit drug abuse, harmful alcohol use\n\nNote: Other protocol defined criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigational Site","city":"La Jolla","state":"California","zip":"92037","country":"United States","geoPoint":{"lat":32.84727,"lon":-117.2742}},{"facility":"Investigational Site","city":"Long Beach","state":"California","zip":"90808","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Investigational Site","city":"San Jose","state":"California","zip":"95117","country":"United States","geoPoint":{"lat":37.33939,"lon":-121.89496}},{"facility":"Investigational Site","city":"Torrance","state":"California","zip":"90505","country":"United States","geoPoint":{"lat":33.83585,"lon":-118.34063}},{"facility":"Investigational Site","city":"Normal","state":"Illinois","zip":"61761","country":"United States","geoPoint":{"lat":40.5142,"lon":-88.99063}},{"facility":"Investigational Site","city":"Kansas City","state":"Missouri","zip":"66160","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Investigational Site","city":"Edmond","state":"Oklahoma","zip":"73034","country":"United States","geoPoint":{"lat":35.65283,"lon":-97.4781}},{"facility":"Investigational Site","city":"Philadelphia","state":"Pennsylvania","zip":"19140","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Investigational Site","city":"Pittsburgh","state":"Pennsylvania","zip":"15241","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"Investigational Site","city":"Bradford","state":"West Yorkshire","zip":"BD9 6RJ","country":"United Kingdom","geoPoint":{"lat":53.79391,"lon":-1.75206}},{"facility":"Investigational Site","city":"Manchester","zip":"M23 9QZ","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D001249","term":"Asthma"}],"ancestors":[{"id":"D001982","term":"Bronchial Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D008173","term":"Lung Diseases, Obstructive"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012130","term":"Respiratory Hypersensitivity"},{"id":"D006969","term":"Hypersensitivity, Immediate"},{"id":"D006967","term":"Hypersensitivity"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false}
]}